[go: up one dir, main page]

MX2019015508A - Nanopartículas para el tratamiento del cáncer. - Google Patents

Nanopartículas para el tratamiento del cáncer.

Info

Publication number
MX2019015508A
MX2019015508A MX2019015508A MX2019015508A MX2019015508A MX 2019015508 A MX2019015508 A MX 2019015508A MX 2019015508 A MX2019015508 A MX 2019015508A MX 2019015508 A MX2019015508 A MX 2019015508A MX 2019015508 A MX2019015508 A MX 2019015508A
Authority
MX
Mexico
Prior art keywords
nanoparticles
treatment
cancer
cells
preparation
Prior art date
Application number
MX2019015508A
Other languages
English (en)
Inventor
Navarro Adrian Daneri
Camacho Antonio Topete
Escareño Abraham Noé Rosas
Original Assignee
Univ Guadalajara
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Guadalajara filed Critical Univ Guadalajara
Priority to MX2019015508A priority Critical patent/MX2019015508A/es
Priority to EP20901619.5A priority patent/EP4101471A4/en
Priority to PCT/IB2020/061716 priority patent/WO2021124028A1/es
Priority to US17/787,791 priority patent/US20230285457A1/en
Publication of MX2019015508A publication Critical patent/MX2019015508A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0042—Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Ceramic Engineering (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)

Abstract

La presente invención está relacionada con nanopartículas fotoresponsivas de liberación estimulada y su uso como una nueva estrategia para proveer un tratamiento antitumoral para cáncer de mama con especificidad incrementada. Se describen células Natural Killer (NK) con gránulos citotóxicos cargados de las nanopartículas fotoresponsivas de liberación estimulada biocompatibles, así como métodos para su preparación.
MX2019015508A 2019-12-18 2019-12-18 Nanopartículas para el tratamiento del cáncer. MX2019015508A (es)

Priority Applications (4)

Application Number Priority Date Filing Date Title
MX2019015508A MX2019015508A (es) 2019-12-18 2019-12-18 Nanopartículas para el tratamiento del cáncer.
EP20901619.5A EP4101471A4 (en) 2019-12-18 2020-12-09 NANOPARTICLES FOR CANCER TREATMENT
PCT/IB2020/061716 WO2021124028A1 (es) 2019-12-18 2020-12-09 Nanopartículas para el tratamiento del cáncer
US17/787,791 US20230285457A1 (en) 2019-12-18 2020-12-09 Nanoparticles for cancer treatment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2019015508A MX2019015508A (es) 2019-12-18 2019-12-18 Nanopartículas para el tratamiento del cáncer.

Publications (1)

Publication Number Publication Date
MX2019015508A true MX2019015508A (es) 2021-06-21

Family

ID=76478260

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019015508A MX2019015508A (es) 2019-12-18 2019-12-18 Nanopartículas para el tratamiento del cáncer.

Country Status (4)

Country Link
US (1) US20230285457A1 (es)
EP (1) EP4101471A4 (es)
MX (1) MX2019015508A (es)
WO (1) WO2021124028A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115152750B (zh) * 2022-07-16 2024-01-26 杭州星空男孩新材料科技有限公司 一种长效抗菌喷雾剂及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7999161B2 (en) 2005-01-22 2011-08-16 Alexander Oraevsky Laser-activated nanothermolysis of cells
DE102005039579B4 (de) 2005-08-19 2022-06-30 Magforce Ag Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen
EP1834646B1 (en) 2005-10-26 2016-06-22 Toto Ltd. Ultrasonic cancer therapy accelerator and cytotoxic agent
ES2866623T3 (es) 2008-11-24 2021-10-19 Massachusetts Inst Technology Métodos y composiciones para el suministro localizado de nanopartículas a un tumor
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
US8664198B2 (en) 2011-02-28 2014-03-04 The University Of Central Oklahoma Immunologically modified carbon nanotubes for cancer treatment
PT2508207E (pt) 2011-03-31 2013-07-22 Bioalliance Pharma Nanopartículas carregadas com um medicamento antitumoral quimioterapêutico
US20150037252A1 (en) 2011-04-20 2015-02-05 The University Of Sydney Method for the Treatment of a Solid Tumour
US20130039954A1 (en) 2011-07-29 2013-02-14 Selecta Biosciences, Inc. Control of antibody responses to synthetic nanocarriers
CA2906514C (en) 2013-03-14 2021-07-27 Jonathan Schneck Nanoscale artificial antigen presenting cells
WO2016145578A1 (en) 2015-03-13 2016-09-22 Syz Cell Therapy Co. Methods of cancer treatment using activated t cells
US10835605B2 (en) * 2015-10-01 2020-11-17 University Of South Carolina Preparations of poly(lactic-co-glycolic acid)/polydopamine core/shell hybrid nanoparticle for photothermal applications

Also Published As

Publication number Publication date
EP4101471A4 (en) 2024-01-10
EP4101471A1 (en) 2022-12-14
WO2021124028A1 (es) 2021-06-24
US20230285457A1 (en) 2023-09-14

Similar Documents

Publication Publication Date Title
DOP2020000050A (es) Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp-1) y usos de los mismos
CL2020002914A1 (es) Métodos y composiciones para tratar el cáncer
CO2020010956A2 (es) Composiciones y métodos para el tratamiento del cáncer y de trastornos inmunitarios usando bacterias de veillonella
MX2023007841A (es) Metodos, composiciones y componentes relacionados con crispr-cpf1 para la inmunoterapia contra el cancer.
PH12019501959A1 (en) Therapeutic rna
MX2023014569A (es) Anticuerpos anti-sirpa.
CO2019008783A2 (es) Compuestos dinucleotidos ciclicos para el tratamiento del cancer
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
NZ737318A (en) Bacteria engineered to reduce hyperphenylalaninemia
PE20191303A1 (es) Compuestos con actividad antitumoral contra celulas cancerosas que tienen mutaciones en el exon 20 de egfr o her2
EA201991607A1 (ru) Генетически модифицированные клетки-натуральные киллеры
MX2022001105A (es) Anticuerpos anti tigit.
MX2018001074A (es) Celulas asesinas naturales y lineas de celulas asesinas naturales modificadas con aumento de la citotoxicidad.
SV2017005355A (es) Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas
PH12016501680B1 (en) Anti-egfrviii antibodies and uses thereof
UY36075A (es) Derivados de tubulisina
MX2022012013A (es) Composiciones y metodos para transduccion de tumores.
CO2020001981A2 (es) Proteínas que se unen a nkg2d, cd16 y flt3
MX2015009277A (es) Formas de dosificacion y usos terapauticos de l-4-cloro quinurenina.
CO2020004984A2 (es) Proceso para preparar el benzotiofen-2-il boronato
MX2016009056A (es) Composiciones y metodos para tratamiento de crecimiento celular anormal.
MX2019015508A (es) Nanopartículas para el tratamiento del cáncer.
MX2024007888A (es) Nanopartículas para el tratamiento del cáncer.
CL2018003184A1 (es) Una composición inmunogénica para el tratamiento del cáncer y métodos para preparar la misma
MX2020006368A (es) Uso de tratamiento combinado de anticuerpo pd-1 y apatinib para tratar cancer de mama triple negativo.